PHARMAC invites tenders for the supply of certain pharmaceuticals to DHB hospitals and/or to community pharmacies in New Zealand.
PHARMAC is seeking feedback on a proposal to list medical devices supplied by O&M Halyard Pty Limited Medical Limited in Part III of Section H of the Pharmaceutical Schedule from 1 February 2020.
Closes: 4pm, Friday 22 November 2019.
Proposal to widen access to rituximab and change the funded brand for all funded indications excluding rheumatoid arthritis
PHARMAC is seeking your feedback on a proposal to make changes to the funded brand of rituximab, a biologic medicine used to treat a range of cancer, blood and autoimmune conditions, from 1 March 2020.
Closes: 12pm, Thursday 14 November 2019.
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2018/19 Invitation to Tender dated 1 November 2018.
We are proposing to make changes to the funding of apomorphine hydrochloride, a medicine used to treat advanced Parkinson’s disease, through an agreement with Stada.
PHARMAC is seeking your feedback only on the proposal to change the Special Authority criteria for bortezomib.
Closes: 4pm, Wednesday 6 November 2019.
PHARMAC is seeking feedback on a proposal to make changes to the funded brands of fluticasone and fluticasone with salmeterol metered dose inhalers (MDIs), which are used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Closes: 4pm, Wednesday 6 November 2019.
Proposal to increase the subsidy for hexamine hippurate tablets and for flecainide acetate injection - DEADLINE EXTENDED TO 5PM FRIDAY 25 OCTOBER 2019
We are seeking feedback on a proposal to increase the subsidy payable for two currently funded treatments through a provisional agreement with Radiant Health Limited.
Closes: 5pm Friday, 25 October 2019.
PHARMAC is advising all interested parties that there is a further delay in the listing of a new funded brand of atomoxetine and removal of the current funding restrictions. The following reflects the most up-to-date information.
PHARMAC is widening funded access to Mirena, as well as listing a new long-acting reversible contraceptive option, Jaydess, which will benefit around 21,000 New Zealand women.
We’re pleased to announce a decision to widen access to levonorgestrel intrauterine systems (LIUS), brand name Mirena, and list a new LIUS, brand name Jaydess.
Decision to list respiratory care products supplied by ConvaTec (New Zealand) Ltd and EBOS Group Limited
We are pleased to announce the approval of non-exclusive listing agreements with ConvaTec (New Zealand) Ltd and EBOS Group Limited for the supply of respiratory equipment and consumable products to DHBs.
We are pleased to announce the approval of a listing agreement with Medtronic New Zealand Limited for listing of medical devices in Part III of Section H of the Pharmaceutical Schedule from 1 November 2019.
We are pleased to announce the approval of listing agreements with Culpan Distributors for urology and continence products and Reynard Health Supplies Limited for continence products in Part III of Section H of the Pharmaceutical Schedule from 1 November 2019.
420 New Zealanders with lung cancer, breast cancer, multiple sclerosis and respiratory disease will benefit each year from a bundle deal PHARMAC has finalised with a medicine supplier.
The agreement with Roche Products (New Zealand) includes funding three new treatments, as well as widened access to one currently funded treatment.
PHARMAC is seeking feedback on a proposal to list a range of medical devices supplied by 3M New Zealand Limited in Part III of Section H of the Pharmaceutical Schedule from 1 December 2019.
Closes: 1pm, Tuesday 29 October 2019.
We’re pleased to announce a decision to approve funding for oncology, multiple sclerosis and respiratory treatments.
PHARMAC is seeking feedback on a proposal to list a range of medical devices supplied by Jackson Allison Medical and Surgical Limited in Part III of Section H of the Pharmaceutical Schedule from 1 December 2019.
Closes: 4pm, Thursday 24 October 2019.
PHARMAC’s annual tender e-portal is now available for suppliers to trial.
Before the e-portal goes ‘live’, PHARMAC is providing suppliers with the opportunity to trial and practice with the e-portal and register their company in the system, if they have not already done so, before the release of the 2019/20 Tender. The practice tender will remain open until midnight on Sunday 19 October 2019.
From today there will be one funded brand of lamotrigine - a medicine used to treat epilepsy and some mental health conditions, including bipolar disorder.
There are several suppliers that make lamotrigine – each with their own brand. PHARMAC has decided to change from funding three different brands (Lamictal, Arrow-Lamotrigine and Logem) to funding the Logem brand only.